Dog · Canis lupus familiaris · typical adult weight 2.00–80.00 kg
Pasireotide is dosed at 0.03–0.1 mg/kg SC q12h (SC) or monthly (LAR) in dogs, per Corroborated 2026-07-31: Lottati M, Bruyette DS. J Am Vet Med Assoc 2018;252(11):1403-1408. doi:10.2460/javma.252.11.1403 PMID:29772978 - dog, pituitary-dependent hyperadrenocorticism with macroadenoma, pasireotide 0.03 mg/kg SC q12h for 6 mo added to trilostane or mitotane.. Pasireotide is used in dogs for Pituitary-dependent hyperadrenocorticism. Routes documented in dogs: SC. A typical adult dog weighs 2.00–80.00 kg. ExoticRx lists 1 cited dose rule for Pasireotide in dogs, drawn from published veterinary references. Verify against current literature before clinical use.
US trade names: Signifor
| Route | Dose | Frequency | Duration | Indication | Evidence | Source |
|---|---|---|---|---|---|---|
| SC | 0.03–0.1 mg/kg | q12h (SC) or monthly (LAR) | Investigational; long-term for Cushing's | Pituitary-dependent hyperadrenocorticism | Weak | Corroborated 2026-07-31: Lottati M, Bruyette DS. J Am Vet Med Assoc 2018;252(11):1403-1408. doi:10.2460/javma.252.11.1403 PMID:29772978 - dog, pituitary-dependent hyperadrenocorticism with macroadenoma, pasireotide 0.03 mg/kg SC q12h for 6 mo added to trilostane or mitotane. |
Need the exact dose for your patient?
These ranges are per kg. Enter your dog's weight to get the precise dose and draw-up volume — unit and concentration math done for you.
Somatostatin analogue with broad somatostatin receptor affinity (SST1,2,3,5) that suppresses ACTH secretion from corticotroph adenomas.
Hyperglycemia is very common. Monitor blood glucose. Investigational for pituitary-dependent hyperadrenocorticism in dogs.
Species-specific contraindications and adverse-reaction reports for dogs may differ from canine / feline reference data — consult the primary citations listed with each rule.
Pasireotide dose range in dogs, with cited source references: SC 0.03–0.1 mg/kg q12h (SC) or monthly (LAR). Reference ranges from cited sources — verify against current literature before clinical use.
Documented routes for Pasireotide in dogs: SC.
Cited course lengths for Pasireotide in dogs include: Investigational; long-term for Cushing's. Duration depends on the indication — match it to the specific dose rule in the table above.
Pasireotide is indicated in dogs for: Pituitary-dependent hyperadrenocorticism.
These are general warnings for Pasireotide across species; consult the dog dosing table above for species-specific guidance. Hyperglycemia is very common. Monitor blood glucose. Investigational for pituitary-dependent hyperadrenocorticism in dogs.
Why a species-specific page? Pasireotide pharmacokinetics differ across species: dose ranges, intervals, and route preferences are not interchangeable. Cross-extrapolation from canine doses is unsafe in dogs — the rules above are the citations specific to this species, not generic recommendations.
Sourced from published veterinary references; awaiting credentialed clinical reviewer. See our editorial process. Reference only — not veterinary advice.